News | October 10, 2025
Thermo Fisher launches new test to assess lung transplant rejection
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
The boy becomes India’s youngest recipient to undergo bilateral lung transplantation.
Donor families honoured as Apollo highlights over 27,500 transplants performed and calls for greater public participation in organ donation
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
